Florida / New York

Ph: 561.316.3330

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES

The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.

This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.

Stryker
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES

Stryker Reports: 1st European Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

The Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures. Its nail design is informed by Stryker’s SOMA database, which includes over 37,000 3D bone models generated from CT scans. The system received CE certification in November 2023 and has been utilized in over 25,000 cases in North America and Japan.

Read More »
Tandem Mobi Insulin Pump
MEDICAL DEVICES, TECHNOLOGIES, EQUIPMENT, SUPPLIES

Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM

The Tandem Mobi Insulin pump is small enough to be worn almost anywhere, including a coin pocket, providing users with more discretion, comfort, and options for how they manage their diabetes. Powered by Control-IQ technology, which has demonstrated in real-world studies improved time in range overnight and during the day4, Tandem Mobi connects with Dexcom G7 or Dexcom G6 to predict glucose levels 30 minutes in advance and automatically adjusts insulin, if needed, to help prevent highs and lows.

Read More »

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Ted Raad, Chief Executive Officer of Pulmatrix, commented, “MannKind’s interest in iSPERSE™ validates the enablement potential of our innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway further into 2026. We are able to build upon this agreement to further support development of PUR3100 and its potential application with MannKind’s Cricket® device to develop the 1st orally inhaled DHE treatment for acute migraine.”

Read More »